Price movement over the last 24 hours
Alcon AG vs Regeneron Pharmaceuticals Inc — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Regeneron Pharmaceuticals Inc trades at $662.85 (market cap $70.90B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.2× Alcon AG's market cap, and Regeneron Pharmaceuticals Inc pays the higher dividend (0.56%). Which is the better fit depends on your goals.
| ALC | REGN | |
|---|---|---|
Market Cap | $32.69B | $70.90B |
Sector | Health | Health |
52-Week High | $92.22 | $812.27 |
52-Week Low | $62.02 | $542.52 |
Enterprise Value | $36.28B | $64.85B |
Dividend Yield | 0.54% | 0.56% |
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →